tiprankstipranks
Trending News
More News >
Vibe Bioscience (TSE:VIBE)
:VIBE
Canadian Market

Vibe Bioscience Ltd (VIBE) AI Stock Analysis

Compare
9 Followers

Top Page

TS

Vibe Bioscience Ltd

(VIBE)

Rating:47Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
The overall stock score is heavily influenced by critical financial performance issues, including declining revenues, negative equity, and persistent losses. While technical analysis shows some positive momentum, it is not sufficient to offset the severe financial constraints. The stock's valuation is further weakened by its negative P/E ratio and lack of dividend yield.

Vibe Bioscience Ltd (VIBE) vs. iShares MSCI Canada ETF (EWC)

Vibe Bioscience Ltd Business Overview & Revenue Model

Company DescriptionVibe Bioscience Ltd (VIBE) is a cannabis company that engages in the cultivation, production, and retail of high-quality cannabis products. The company operates in the legal cannabis sector and focuses on providing a diverse range of products including flowers, edibles, concentrates, and other cannabis-infused products. VIBE is committed to delivering exceptional customer experiences through its retail dispensaries and online platforms, while adhering to regulatory compliance and sustainable practices.
How the Company Makes MoneyVibe Bioscience Ltd makes money primarily through the sale of cannabis products. Its key revenue streams include retail sales from its dispensaries and e-commerce platforms, where customers can purchase various cannabis products. The company also generates revenue from the cultivation and wholesale distribution of cannabis to other businesses. Additionally, VIBE may engage in strategic partnerships and branding initiatives to enhance its market presence and drive sales. The company's earnings are influenced by factors such as consumer demand, regulatory changes, and market competition within the cannabis industry.

Vibe Bioscience Ltd Financial Statement Overview

Summary
Vibe Bioscience Ltd is experiencing severe financial difficulties, with declining revenues, persistent losses, and negative equity. The balance sheet indicates significant solvency issues, and while cash flow has shown slight improvement, the overall financial condition remains precarious.
Income Statement
40
Negative
Vibe Bioscience Ltd has experienced a significant decline in revenue over the years, with a noticeable decrease from $24.2M in 2020 to $12.7M in 2024. Gross profit margins have also deteriorated, falling from 35.2% in 2020 to 37.2% in 2024. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. The net profit margin has remained negative, highlighting profitability issues. Overall, the income statement reflects a company struggling with declining revenues and persistent losses.
Balance Sheet
25
Negative
The balance sheet of Vibe Bioscience Ltd presents significant concerns. The company's stockholders' equity turned negative in 2024, indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, which is a red flag for leverage risk. The equity ratio has shifted from 55.1% in 2020 to negative in 2024, demonstrating weakened financial stability. Overall, the balance sheet shows a company with high liabilities and diminishing asset base, posing a risk to financial health.
Cash Flow
45
Neutral
The cash flow statement shows some improvement in free cash flow in 2024, rising to $202,824 from a negative position in previous years. Operating cash flow turned positive in 2024, a positive sign, but the company still faces challenges with consistent negative free cash flow in past periods, indicating cash management issues. The operating cash flow to net income ratio is positive but low due to negative net income, suggesting operational cash generation struggles. Overall, the cash flow situation, while slightly improving, remains concerning.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.71M14.15M20.71M29.29M24.24M
Gross Profit4.74M5.17M6.49M8.42M8.54M
EBITDA-3.91M-8.42M-3.07M-1.11M3.05M
Net Income-6.54M-11.13M-9.45M-4.30M728.55K
Balance Sheet
Total Assets11.29M16.28M25.89M32.90M18.34M
Cash, Cash Equivalents and Short-Term Investments1.06M1.17M4.55M9.10M2.41M
Total Debt2.57M2.89M3.38M2.83M2.57M
Total Liabilities16.51M15.20M13.63M11.50M8.23M
Stockholders Equity-5.22M1.08M12.26M21.39M10.11M
Cash Flow
Free Cash Flow202.82K-2.78M-3.71M-7.20M193.36K
Operating Cash Flow233.74K-2.71M-1.97M848.73K724.34K
Investing Cash Flow19.02K-71.80K-1.75M-8.43M362.35K
Financing Cash Flow-360.37K-595.55K-699.14K14.33M-324.15K

Vibe Bioscience Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.07
Positive
100DMA
0.06
Positive
200DMA
0.08
Negative
Market Momentum
MACD
0.01
Negative
RSI
47.03
Neutral
STOCH
43.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VIBE, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.03 is Neutral, neither overbought nor oversold. The STOCH value of 43.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VIBE.

Vibe Bioscience Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
47
Neutral
C$863.76K-201.37%5.13%41.24%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
25
Underperform
C$463.19K39.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:VIBE
Vibe Bioscience Ltd
0.08
-0.02
-20.00%
TSE:CNTR
CENTR Brands
0.04
-0.16
-80.00%

Vibe Bioscience Ltd Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance
Vibe Growth Director to Reduce Stake with Share Sale
Neutral
Jul 2, 2025

Mark Waldron, a director at Vibe Growth Corporation, has filed an Early Warning Report indicating his intention to sell 250,000 common shares of the company through the Canadian Securities Exchange. This move will reduce Waldron’s stake from 18.14% to 15.83% of the company’s outstanding shares. The sale is part of Waldron’s strategy to decrease his holdings and utilize the proceeds for other purposes, though he remains open to future transactions based on market conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025